- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05397613
STAIR for Trauma and Emotion Dysregulation
May 25, 2022 updated by: Sanno Zack, Stanford University
Examining the Effectiveness of STAIR as an Alternative to DBT for Patients With Emotion Dysregulation and PTSD
This study will examine the impact of Skills Training in Affective and Interpersonal Regulation (STAIR) group, using self-report measures, on Posttraumatic Stress Disorder (PTSD), emotional dysregulation, borderline personality disorder symptoms, global psychopathology, and access to quality mental health care.
Aims include assessing the feasibility of STAIR, reducing patients' trauma and emotion dysregulation symptoms, examining whether STAIR may be used as an alternative to DBT for patients on the DBT, and improving patient satisfaction and clinic efficiency
Study Overview
Status
Enrolling by invitation
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Be 18 years or older.
- Have a DSM-5 diagnosis and/or symptoms for which DBT is an indicated treatment
- Meet DSM-5 criteria for a diagnosis of posttraumatic stress disorder (PTSD)
- Meet criteria at a subclinical level for BPD (a minimum of three symptoms)
- Must be able to make group commitments for attendance, safety, and sobriety during group
Exclusion Criteria:
- If currently receiving individual therapy that follows the DBT protocol or is an evidence-based trauma-focused therapy
- If the STAIR therapy group is determined to be clinically contraindicated
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: STAIR
Participants will complete 1.5 hr group sessions once per week for 12 weeks of Skills Training in Affective and Interpersonal Regulation (STAIR).
Participants will complete self-report measures pre, post, and at one month intervals.
|
Clinician led session that hones in on a particular deficit within these skills, including identifying and labeling emotions, managing emotions, tolerating distress, accepting feelings and increasing positive emotions, identifying trauma-based interpersonal schemas, identifying conflict between trauma-related feelings and goals, role plays surrounding issues of power and control, and role-plays related to developing flexibility in interpersonal situations involving power differentials.
STAIR is a cognitive-behavioral treatment that addresses emotion regulation and interpersonal difficulties and their impact on daily living.
|
|
Experimental: Waitlist control
First, participants will remain on the DBT waitlist for 12 weeks receiving no active intervention and will complete pre and post-measures.
Then participants will complete 1.5 hr group sessions once per week for 12 weeks of Skills Training in Affective and Interpersonal Regulation (STAIR).
Participants will complete self-report measures pre, post, and at one month intervals.
|
Clinician led session that hones in on a particular deficit within these skills, including identifying and labeling emotions, managing emotions, tolerating distress, accepting feelings and increasing positive emotions, identifying trauma-based interpersonal schemas, identifying conflict between trauma-related feelings and goals, role plays surrounding issues of power and control, and role-plays related to developing flexibility in interpersonal situations involving power differentials.
STAIR is a cognitive-behavioral treatment that addresses emotion regulation and interpersonal difficulties and their impact on daily living.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants who complete the STAIR intervention
Time Frame: Week 12
|
This number will include those who attend the 12 weeks of STAIR with no more than three missed sessions
|
Week 12
|
|
Total score of patient treatment satisfaction ratings
Time Frame: Week 12
|
Calculate the total score for each participant on the Client Satisfaction Questionnaire-8, and find the average of those scores.
Scores are summed across items.
Items 2, 4, 5, and 8 are reverse scored.
Total scores range from 8 to 32, with the higher number indicating greater satisfaction.
|
Week 12
|
|
Frequency of participant attendance
Time Frame: Week 1 through Week 12
|
Calculate the number of patients who attended each week of the STAIR treatment.
|
Week 1 through Week 12
|
|
Change in emotion regulation total score from baseline to Week 12
Time Frame: Baseline to Week 12
|
Problems with emotion regulation will be assessed using the Difficulty in Emotion Regulation Scale.
Total score ranges from 36 to 180.
Higher scores indicate greater problems with emotion regulation.
|
Baseline to Week 12
|
|
Change in the severity of posttraumatic stress disorder symptom total score from baseline to Week 12
Time Frame: Baseline to Week 12
|
The severity of posttraumatic stress disorder symptoms is measured using the PCL-5.
Items are rated using a 5-point likert scale ranging from 0 "not at all" to 4 "extremely."
All 20 items are summed to obtain a total score (0 to 80), higher scores indicate higher severity of PTSD symptoms.
|
Baseline to Week 12
|
|
Change in Borderline symptom severity total score from baseline to Week 12
Time Frame: Baseline and Week 12
|
Using the Borderline Evaluation of Severity Scale comprising of 15 items using a likert scale rated from 5 "Almost Always" to 1 "Almost Never."
There are three subscales that comprise this measure: (1) Thoughts and Emotions (2) Behaviors-Negative and (3) Behaviors-Positive.
The total for each subscale is determined to score the BEST.
The scores of subscales A and B are then added together and the total from subscale C is subtracted.
A correction factor of 15 is added to yield the final score which can range from 12 (best) to 72 (worst).
|
Baseline and Week 12
|
|
Change in Borderline Symptom List-23 total score from baseline to Week 12
Time Frame: Baseline and Week 12
|
This measure assesses feelings and experiences commonly endorsed by patients with BPD.
The 23-item scale utilizes a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very strong."
The BSL-23 is scored by summing up the scores for all of the items.
Total score ranges from 0 to 92, with higher scores reflecting more severe borderline personality symptoms.
|
Baseline and Week 12
|
|
Change in current symptoms of psychopathology and psychological distress total score from baseline to Week 12
Time Frame: Baseline and Week 12
|
The Symptom Checklist-90-Revised is a 90-item multidimensional self-report symptom measure that assesses current symptoms of psychopathology and psychological distress.
The items were scored on a 5-point Likert scale ranging from 0 (not at all) to 4 (extremely).
It assesses nine symptom dimensions (somatization, obsessive compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, psychoticism).
Global measures are provided to summarize overall distress, and these include the Global Severity Index, Positive Symptom Distress Index, and Positive Symptom Total.
Raw scores are calculated by dividing the sum of scores for a specific dimension by the number of items in the dimension.
Global severity index is calculated by summing the scores of the nine dimensions and additional items, then dividing by the total number of responses.
Total score ranges from 0 to 360.
Higher scores indicate worsening of disease.
|
Baseline and Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sanno Zack, PhD, Stanford Universtiy
- Principal Investigator: Emily Livermore, PsyD, Stanford University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
June 15, 2022
Primary Completion (Anticipated)
June 15, 2025
Study Completion (Anticipated)
June 15, 2025
Study Registration Dates
First Submitted
May 24, 2022
First Submitted That Met QC Criteria
May 25, 2022
First Posted (Actual)
May 31, 2022
Study Record Updates
Last Update Posted (Actual)
May 31, 2022
Last Update Submitted That Met QC Criteria
May 25, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 64219
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Borderline Personality Disorder
-
University of California, Los AngelesRecruitingBorderline Personality Disorder | Borderline Personality | BPD - Borderline Personality DisorderUnited States
-
University Hospital, Basel, SwitzerlandLeading House for the Latin American Region (Seed Money Grant SMG 1730)WithdrawnBorderline Personality Disorder (BPD)
-
Waypoint Centre for Mental Health CareRecruitingBorderline Personality Disorder (BPD)Canada
-
Mclean HospitalRecruitingBorderline Personality Disorder (BPD)United States
-
University Hospital, MontpellierNot yet recruitingBorderline Personality Disorder | Borderline Personality Disorder (BPD)
-
Health Service Executive, IrelandCompletedPersonality Disorder, Borderline
-
University Hospital, ToulouseNot yet recruitingBorderline Personality Disorder (BPD) | Infusion of Ketamine in Severe Borderline Personality DisorderFrance
-
IRCCS Centro San Giovanni di Dio FatebenefratelliCompletedBorderline Personality Disorder (BPD)Italy
-
University of EdinburghCompletedEmotionally Unstable Personality Disorder, Borderline TypeUnited Kingdom
-
Hospital Universitari Vall d'Hebron Research InstituteUnknownBorderline Personality Disorder.Spain
Clinical Trials on STAIR
-
Teesside UniversityCompletedBlood Pressure | Heart Rate | Physical Activity Enjoyment | High-intensity Interval Exercise | Rating of Perceived Exertion | Acute MoodUnited Kingdom
-
IRCCS Eugenio MedeaIstituti Clinici Scientifici Maugeri SpA; Politecnico di Milano; ASP Istituti...RecruitingStair Climbing | Instrumentation | TestItaly
-
San Diego State UniversityCompletedPostprandial Blood GlucoseUnited States
-
Children's Hospital of PhiladelphiaNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingDuchenne Muscular Dystrophy (DMD) | Becker's Muscular Dystrophy (BMD)United States
-
Cancer Institute and Hospital, Chinese Academy...Completed
-
University of GeorgiaCompleted
-
San Diego State UniversityCompletedPostprandial Hyperglycemia
-
NYU Langone HealthWithdrawn
-
Kaohsiung Veterans General Hospital.CompletedChronic Stroke Patients
-
Harvard Medical School (HMS and HSDM)Aga Khan UniversityNot yet recruitingFacilatated STAIR Coach